

# CALL FOR PAPERS

*CNS Spectrums* is accepting submissions of **case reports, review articles, and original research** on a variety of neuroscientific and clinical neuropsychiatric topics.

## **Examples of topics include:**

- **Clinical interface of psychiatry and neurology**
- **Neurology and neuropsychiatry in a clinical setting addressing spectrum disorders**
- **Applications of psychopharmacology and pharmacokinetics across the neuropsychiatric spectrum**

Especially encouraged are papers covering comorbidities in neurologic disorders (eg, epilepsy with schizophrenia). Other crossover manuscripts geared to deepening the clinician's understanding of neuropsychiatric disorders and treatments will be given highest priority. (Please see the Author Guidelines at [www.cnsspectrums.com/asp/authorguidelines.aspx](http://www.cnsspectrums.com/asp/authorguidelines.aspx)).

**MBL Communications, Inc., is proud to announce the 2005 ISI Journal Citation Reports' impact factor for *CNS Spectrums*. The current impact factor of 2.037 for *CNS Spectrums* and is based on a total of 580 citations.** *CNS Spectrums'* impact factor is ranked 58 out of 148 journals in the ISI Journal Citation Report's Clinical Neurology category and 48 out of 94 journals in the Psychiatry category—the top half of the psychiatry journals worldwide.

*CNS Spectrums* has the largest circulation in the nation among *Index Medicus*-approved neuropsychiatric publications with a monthly readership of 50,000 neurologists and psychiatrists.

Submissions should be sent to Eric Hollander, MD, Editor (In Europe, to Joseph Zohar, MD, International Editor), c/o Virginia Jackson, Acquisitions Editor, *CNS Spectrums*, c/o MBL Communications, 333 Hudson Street, 7th Floor, New York, NY 10013, E-mail: [vj@mblcommunications.com](mailto:vj@mblcommunications.com).

**PRIMARY PSYCHIATRY**  
The Leading Voice of Clinical Psychiatric Medicine

**CNS SPECTRUMS**  
The International Journal of Neuropsychiatric Medicine

**Psychiatry Weekly**  
The Leading News Service From Primary Psychiatry® and Physician's Weekly®

*A Global Commitment to Advancing CNS Science, Clinical Practice, and Evidence-Based Medicine*

# REDEFINING 24/7 ACCESS TO CLINICAL CONTENT

Revisit CNS Spectrums' Enhanced Web Portal...

[www.cnsspectrums.com](http://www.cnsspectrums.com)

**AVAILABLE NOW\***

**FREE**  
Downloadable  
Psychiatric Podcasts!



@ [www.cnsspectrums.com](http://www.cnsspectrums.com)  
and available on iTunes



\*Click on the **red PsychCast™** button at [www.cnsspectrums.com](http://www.cnsspectrums.com)

CNS Spectrums' Web portal is now better than ever — a one-stop source providing the following integrated services based on input from you... *our readers*:

- **Most-Read Articles** automatically tabulated
- **Quick Links** to Clinical Review Articles, Columns, News, & Educational Reviews
- **Keyword or Disease State-Based Article Search**
- **eSubmissions & eReprints**
- **Integrated Customer-Service Tools**
- **eLearning** via Enduring Materials & Monthly CME Section
- And a host of additional services and features... including simple hyperlink access to MBL's other CNS sources: [www.primarypsychiatry.com](http://www.primarypsychiatry.com) and [www.psychiatryweekly.com](http://www.psychiatryweekly.com)

To learn more, please visit [www.cnsspectrums.com](http://www.cnsspectrums.com) or [www.mblcommunications.com](http://www.mblcommunications.com)

**PRIMARY PSYCHIATRY™**  
The Leading Voice of Clinical Psychiatric Medicine

**CNS SPECTRUMS™**  
The International Journal of Neuropsychiatric Medicine

**Psychiatry Weekly™**  
The Leading News Service From Primary Psychiatry™ and Physician's Weekly®

*A Global Commitment to Advancing CNS Science, Clinical Practice, and Evidence-Based Medicine*



Control acute agitation with

# GEODON<sup>®</sup>

for *Injection* (ziprasidone mesylate)

In schizophrenia...

## Rapid improvement with low EPS<sup>1,2</sup>

- Significant control achieved between 15 and 30 minutes\* after injection<sup>1,3</sup>
- Proven advantages over haloperidol IM
  - twice the improvement as measured on the BPRS<sup>4†</sup>
  - significantly lower incidence of movement disorders<sup>2‡</sup>
- Smooth transition, with continued improvement, from IM to oral therapy<sup>2,4</sup>
- May be used concomitantly with benzodiazepines

\*In 2 pivotal studies vs control, significance was achieved at 15 minutes (with 10 mg dose) and 30 minutes (with 20 mg dose), respectively.

†In a 7-day, open-label IM-to-oral transition study.

‡In a 6-week, open-label IM-to-oral transition study.



**GEODON<sup>®</sup>**  
*Oral Capsules* (ziprasidone HCl)  
and *Injection* (ziprasidone mesylate)

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. GEODON is not approved for the treatment of patients with dementia-related psychosis.

GEODON is contraindicated in patients with a known history of QT prolongation, recent acute myocardial infarction, or uncompensated heart failure, and should not be used with other QT-prolonging drugs. GEODON has a greater capacity to prolong the QT<sub>c</sub> interval than several antipsychotics. In some drugs, QT prolongation has been associated with torsade de pointes, a potentially fatal arrhythmia. In many cases this would lead to the conclusion that other drugs should be tried first.

In fixed-dose, pivotal studies, the most commonly observed adverse events associated with the use of GEODON for Injection (incidence ≥5%) and observed at a rate in the higher GEODON dose groups (10 mg, 20 mg) of at least twice that of the lowest GEODON dose group (2 mg control) were somnolence (20%), headache (13%), and nausea (12%).

Please see brief summary of prescribing information on adjacent page.